NCT00768989 - Phase IIB Pilot of Atazanavir + Raltegravir | Biotech Hunter

Enrollment

167

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

May 31, 2010

Conditions

HIV

Interventions

DRUG

Atazanavir

Capsules, Oral, 300 mg, twice daily, 96 weeks

DRUG

Raltegravir

Tablet, Oral, 400 mg, twice daily, 96 weeks

DRUG

Atazanavir

Capsules, Oral, 300 mg, once daily, 96 weeks

DRUG

Ritonavir

Capsules, Oral, 100 mg, once daily, 96 weeks

DRUG

Tenofovir/Emtricitabine

Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks

Trial Locations (16)

1141

Local Institution, Buenos Aires, Bs As

1264

Local Institution, Capital Federal

2000

Local Institution, Rosario

10016

The Aaron Diamond AIDS Research Center, New York

20009

Dupont Circle Physicians Group, Washington D.C.

32803

Orlando Immunology Center, Orlando

44035

Local Institution, Nantes

45267

University Of Cincinnati, Cincinnati

75475

Local Institution, Paris

75970

Local Institution, Paris

76104

Tarrant County Infectious Disease Associates, Fort Worth

77004

Therapeutic Concepts, P.A., Houston

77057

Diversified Medical Practices, P.A., Houston

85006

Southwest Center For HIV/AIDS, Phoenix

06510

Yale University School Of Medicine, New Haven

B7600CTO

Local Institution, Mar del Plata